Clicky

TG Therapeutics, Inc.(TGTX) News

Date Title
Sep 5 TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Aug 30 TG Therapeutics Inc (NASDAQ:TGTX) A Bull Case Theory
Aug 12 FDA grants IND clearance for TG Therapeutics’ trial of multiple sclerosis treatment
Aug 9 Results: TG Therapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit
Jul 30 TG Therapeutics, Inc.'s (NASDAQ:TGTX) recent 3.1% pullback adds to one-year year losses, institutional owners may take drastic measures
Jun 26 Stocks To Watch: Biotech Leader TG Therapeutics Clears Resistance Area
Jun 21 Insider Sale: Director Sagar Lonial Sells 25,933 Shares of TG Therapeutics Inc (TGTX)
May 3 TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript
May 3 Rainbows and Unicorns: TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Became A Lot More Optimistic
May 3 Why TG Therapeutics Stock Was Rocketing Higher This Week
May 2 TG Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
May 2 TG Therapeutics Inc (TGTX) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue Growth ...
May 2 Q1 2024 TG Therapeutics Inc Earnings Call
May 1 TG Therapeutics Inc (TGTX) Surpasses Revenue Estimates in Q1 2024, Despite Widening Net Loss
May 1 TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Apr 30 TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
Apr 30 After Plunging -9.82% in 4 Weeks, Here's Why the Trend Might Reverse for TG Therapeutics (TGTX)
Apr 18 TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Apr 18 TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Apr 15 TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting